YishengBio seeks greenlight for Hong Kong IPO

Pharma_drugs_adobe_575x375.jpg
By Jonathan Breen
09 Mar 2021

China’s YishengBio is planning to list in Hong Kong, having filed an IPO application with the bourse on Monday.

YishengBio has hired Haitong International and Morgan Stanley as the sponsors for the deal.

The issuer is a Beijing-headquartered, global biopharmaceutical company that focuses on developing, making and selling new vaccines and therapies for infectious diseases and cancer. It has so far generated revenue from its rabies vaccine ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial